CIK 0001743881
- Large accelerated filer
BridgeBio Pharma, Inc.
Sign in to watch- Ticker
- BBIO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 650-391-9740
- Business address
- 3160 PORTER DR., SUITE 250, PALO ALTO, CA, 94304
- Former names
- BridgeBio Pharma LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,676,804
- in 3 filings, $1.7M under 10b5-1 plans
Net −$1,676,804. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-10-16 | HOMCY CHARLES J Chairman of Pharmaceuticals | Option exercise · Stock Option (Right to Buy) | −10,256 | 260,207 | ||
| 2020-06-03 | HENDERSON MICHAEL THOMAS Chief Business Officer | Sale | −784 | $30.04 | $24K | 261,399 |
| 2020-05-28 | KKR Genetic Disorder L.P. 10% owner | Sale | −2,389,690 | $33.39 | $79.8M | 34,510,971 |
| 2019-07-01 | KKR Genetic Disorder L.P. 10% owner | Conversion | +34,253,561 | 34,253,561 | ||
| 2019-07-01 | KKR Genetic Disorder L.P. 10% owner | Purchase | +2,647,100 | $17.00 | $45.0M | 36,900,661 |
| 2019-07-01 | KKR Genetic Disorder L.P. 10% owner | Conversion · Series B Preferred Units | −81,022,727 | 0 | ||
| 2019-07-01 | KKR Genetic Disorder L.P. 10% owner | Conversion · Series C Preferred Units | −36,246,893 | 0 | ||
| 2019-07-01 | KKR Genetic Disorder L.P. 10% owner | Conversion · Series D Preferred Units | −50,446,451 | 0 |
Page 44 of 44 · 868 trades